{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:51Z","timestamp":1783930371459,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Graduate School, Prince of Songkla University, Thailand"},{"name":"the Thailand Science Research and Innovation Fund, the University of Phayao","award":["(Grant No. 2293\/2568)"],"award-info":[{"award-number":["(Grant No. 2293\/2568)"]}]},{"name":"Faculty of Medicine,Prince of Songkla University, Thailand."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04096-6","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:57:56Z","timestamp":1781150276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK\/PD-guided dosing"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-0039","authenticated-orcid":false,"given":"Apinya","family":"Boonpeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-1407","authenticated-orcid":false,"given":"Sutep","family":"Jaruratanasirikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monchana","family":"Jullangkoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maseetoh","family":"Samaeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"7","key":"4096_CR1","first-page":"1027","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ et al (2007) Comp Rev Carbapenems Drugs 67(7):1027\u20131052","journal-title":"Comp Rev Carbapenems Drugs"},{"issue":"6","key":"4096_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW et al (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14(6):498\u2013509","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37(3):840\u2013851","journal-title":"Crit Care Med"},{"key":"4096_CR4","doi-asserted-by":"crossref","unstructured":"Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL (2007) Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. ;51","DOI":"10.1128\/AAC.01318-06"},{"key":"4096_CR5","doi-asserted-by":"crossref","unstructured":"Couffignal C, Pajot O, Laou\u00e9nan C, Burdet C, Foucrier A, Wolff M et al (2014) Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. 78(5):1022\u20131034","DOI":"10.1111\/bcp.12435"},{"issue":"7","key":"4096_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40262-020-00859-1","volume":"59","author":"F de Velde","year":"2020","unstructured":"de Velde F, de Winter BCM, Neely MN, Yamada WM, Koch BCP, Harbarth S et al (2020) Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. Clin Pharmacokinet 59(7):885\u2013898","journal-title":"Clin Pharmacokinet"},{"key":"4096_CR7","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.2147\/IDR.S373348","volume":"15","author":"TD Dinh","year":"2022","unstructured":"Dinh TD, Nguyen HN, Le BH, Nguyen TTT, Nguyen HTL (2022) Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients. Infect Drug Resist 15:4575\u20134583","journal-title":"Infect Drug Resist"},{"issue":"5","key":"4096_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/ejhpharm-2022-003403","volume":"31","author":"J Bai","year":"2024","unstructured":"Bai J, Wen A, Li Z, Li X, Duan M (2024) Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients. Eur J Hosp Pharm 31(5):434\u2013439","journal-title":"Eur J Hosp Pharm"},{"key":"4096_CR9","unstructured":"Imipenem\/cilastatin [package insert] New Jersey (NJ), USA.: Merck & Co.; [updated 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050587s074lbl.pdf"},{"issue":"2","key":"4096_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J (2011) The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50(2):99\u2013110","journal-title":"Clin Pharmacokinet"},{"key":"4096_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijid.2022.12.010","volume":"127","author":"Y-L Lee","year":"2023","unstructured":"Lee Y-L, Ko W-C, Hsueh P-R (2023) Geographic patterns of <\u2009em>Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012\u20132019. Int J Infect Dis 127:48\u201355","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4096_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0378-4347(96)00498-7","volume":"692","author":"L Garcia-Capdevila","year":"1997","unstructured":"Garcia-Capdevila L, Lopez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J (1997) Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl 692(1):127\u2013132","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"5","key":"4096_CR13","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (Burbank, Los Angeles County. Calif) 5(5):303\u2013311 discussion 12\u2009\u2013\u20093","journal-title":"Calif)"},{"key":"4096_CR14","unstructured":"Pharmacokinetics in patients with impaired renal function \u2013 Study design, data analysis, and impact on dosing: Guidance for industry [Internet]. 2024 [cited 16 Jan 2025]. Available from: https:\/\/www.fda.gov\/media\/78573\/download"},{"issue":"1","key":"4096_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA (1998) Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1\u201310","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4096_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1345\/aph.1E271","volume":"39","author":"RE Ariano","year":"2005","unstructured":"Ariano RE, Nyhl\u00e9n A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA (2005) Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 39(1):32\u201338","journal-title":"Ann Pharmacother"},{"issue":"11","key":"4096_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/11595960-000000000-00000","volume":"28","author":"QT Zhou","year":"2011","unstructured":"Zhou QT, He B, Zhang C, Zhai SD, Liu ZY, Zhang J (2011) Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging 28(11):903\u2013912","journal-title":"Drugs Aging"},{"issue":"11","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"e00845","DOI":"10.1128\/aac.00845-22","volume":"66","author":"A Boonpeng","year":"2022","unstructured":"Boonpeng A, Jaruratanasirikul S, Jullangkoon M, Samaeng M, Wattanavijitkul T, Bhurayanontachai R et al (2022) Population Pharmacokinetics\/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients. Antimicrob Agents Chemother 66(11):e00845\u2013e00822","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4096_CR19","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","volume":"75","author":"MH Al-Shaer","year":"2020","unstructured":"Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C (2020) Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients. J Antimicrob Chemother 75(12):3644\u20133651","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1007\/s00210-023-02909-4","volume":"397","author":"Y Wu","year":"2024","unstructured":"Wu Y, Lu Z, Liang P, Zhu H, Qi H, Zhang H (2024) Relationship of imipenem therapeutic drug monitoring to clinical outcomes in critically ill patients: a retrospective cohort study. Naunyn Schmiedebergs Arch Pharmacol 397(7):4791\u20134798","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4096_CR21","doi-asserted-by":"crossref","unstructured":"Awdishu L, Maxson R, Gratt C, Rubenzik T, Battistella M (2025) KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. Am J Health Syst Pharm","DOI":"10.1093\/ajhp\/zxaf044"},{"issue":"9","key":"4096_CR22","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1128\/AAC.01318-06","volume":"51","author":"SG Sakka","year":"2007","unstructured":"Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL et al (2007) Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 51(9):3304\u20133310","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijantimicag.2016.12.005","volume":"49","author":"H Such\u00e1nkov\u00e1","year":"2017","unstructured":"Such\u00e1nkov\u00e1 H, Lip\u0161 M, Urb\u00e1nek K, Neely MN, Strojil J (2017) Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents 49(3):348\u2013354","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01964413","volume":"10","author":"I Nilsson-Ehle","year":"1991","unstructured":"Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR (1991) Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 10(2):85\u201388","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4096_CR25","doi-asserted-by":"crossref","unstructured":"Norrby SR, Bjornegard B, Ferber F, Jones KH (1983) Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother. ;12 Suppl D:109\u2009\u2013\u200924.","DOI":"10.1093\/jac\/12.suppl_D.109"},{"issue":"1","key":"4096_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jppr.1884","volume":"54","author":"S Mirkov","year":"2024","unstructured":"Mirkov S, Scuderi C, Lloyd J, Coutsouvelis J, O\u2019Connor S, Potts S et al (2024) Estimation of kidney function for medication dosing in adult patients with chronic kidney disease: a practice update. J Pharm Pract Res 54(1):94\u2013106","journal-title":"J Pharm Pract Res"},{"issue":"8","key":"4096_CR27","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/jac\/dku111","volume":"69","author":"JP Cannon","year":"2014","unstructured":"Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA (2014) The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 69(8):2043\u20132055","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04096-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:34Z","timestamp":1783929454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04096-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04096-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Human Research Ethics Committee, Faculty of Medicine, Prince of Songkla University (approval number: REC 61-061-14-1). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the authors used ChatGPT and Claude.ai to improve readability and language. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"170"}}